Pilaralisib (XL147)

Catalog No.S7645

For research use only.

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

Pilaralisib (XL147) Chemical Structure

CAS No. 934526-89-3

Selleck's Pilaralisib (XL147) has been cited by 12 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
PI3Kγ [1] PI3Kβ [1] PI3Kδ [1] PI3Kα [1]
23 nM 36 nM 36 nM 39 nM
In vitro

Pilaralisib exhibits cytotoxic activity in Pediatric Preclinical Testing Program (PPTP) cell lines, with a median relative IC50 value of 10.9 mM (range 2.7 mM to 24.5 mM).[2]

Methods Test Index PMID
Western blot IGF-1R / AKT / MAPK 22113431
Immunofluorescence PAK ; phospho-PAK 23915247
In vivo In BALB/c nu/nu mice, Pilaralisib (100 mg/kg, p.o.) induces tumor growth inhibition for solid glioma xenografts. Pilaralisib is well tolerated, with only 0.7% toxicity rate in the treated groups, similar to that observed for control animals.[2] In athymic female mouse, Pilaralisib (100 mg/kg, p.o.) significantly delays tumor growth without significant drug-related toxicity.[3]

Protocol (from reference)

Kinase Assay: [4]
  • In vitro kinase inhibition assays:

    Kinase activity for PI3K isoforms is measured as the percentage of ATP consumed following the kinase reaction using luciferase–luciferin-coupled chemiluminescence, with ATP concentrations approximately equal to the Km for each respective kinase. Kinase reactions are initiated by combining test compounds, ATP and kinase in a 20 μL volume. PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ final enzyme concentrations are 0.5, 8, 20, and 2 nM, respectively. Of note, 0.5 μL dimethyl sulfoxide (DMSO) containing varying concentrations of the test compound is mixed with 10 μL enzyme solution (2×concentration). Kinase reactions are initiated by the addition of 10 μL of liver phosphatidylinositol and ATP solution (2×concentration). Assay concentrations for VPS34, ATP, and phosphatidylinositol are 40 nM, 1 μM, and 5 μM, respectively

Cell Research:[5]
  • Cell lines: BT474 cells
  • Concentrations: 6 μM
  • Incubation Time: 5 days
  • Method: Cell proliferation is measured by using MTT or pre-mixed WST-1 reagent. For MTT/WST-1 assays, 10,000 cells/well are seeded in 96-well plates. 24 h after plating, cells are treated with DMSO or pilaralisib. After 5 days of treatment, MTT/WST-1 assays are performed.
Animal Research:[2]
  • Animal Models: BALB/c nu/nu mice with glioma xenografts
  • Dosages: 100 mg/kg
  • Administration: p.o.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
10 mM HCl in sterile water
For best results, use promptly after mixing.


Chemical Information

Molecular Weight 541.02


CAS No. 934526-89-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)(C(=O)NC1=CC(=CC=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=C(C=CC(=C4)OC)Cl)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01240460 Completed Drug: XL765 (SAR245409)|Drug: XL147 (SAR245408) Glioblastoma|Astrocytoma Grade IV Sanofi January 2011 Phase 1
NCT01013324 Completed Drug: XL147 (SAR245408) Endometrial Cancer|Endometrial Neoplasms Sanofi January 2010 Phase 2
NCT00756847 Completed Drug: XL147 (SAR245408)|Drug: paclitaxel|Drug: carboplatin Cancer|Non-Small Cell Lung Cancer|Endometrial Carcinoma|Ovarian Carcinoma Sanofi September 2008 Phase 1
NCT00704392 Withdrawn Drug: XL647|Drug: XL147 Cancer|Non-small-cell Lung Cancer|Breast Cancer Exelixis June 2008 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pilaralisib (XL147) | Pilaralisib (XL147) supplier | purchase Pilaralisib (XL147) | Pilaralisib (XL147) cost | Pilaralisib (XL147) manufacturer | order Pilaralisib (XL147) | Pilaralisib (XL147) distributor